Melatonin & Zinc Administration on Cardinal Symptoms in Myalgic

Status Recruiting

Clinical Trial Summary

The aim of the study is to investigate the effects of oral melatonin and zinc supplementation on core features in individuals with ME/CFS

Clinical Trial Description

Myalgic Encephalomyelitis, also known as Chronic Fatigue Syndrome (ME/CFS) is a heterogeneous condition characterized mainly by debilitating and prolonged fatigue, post-exertional malaise (physical, mental and emotional), unrefreshing sleep, cognitive impairment, and orthostatic intolerance with prolonged recovery that is not relieved by rest. Currently, the etiopathogenic mechanisms of ME/CFS are unknown. At present, there is no diagnostic test or effective treatment. MelatoZinc is a food supplement composed of melatonin and zinc, which could contribute to the circadian rhythm homeostasis and regulation of redox imbalance and immune response. The aim is to evaluate the efficacy and safety of oral treatment with MelatoZinc on the symptomatic complex of fatigue in a larger Spanish ME/CFS population. This is a single-center, randomized, double-blind, placebo controlled clinical trial. It will include a total of 106 ME/CFS patients who met 2011 ICC criteria for ME/CFS. All patients will take one capsule daily for 16 weeks. Group A will receive MelatoZinc (1 mg melatonin plus 10 mg zinc), and group B will receive a placebo (excipients: isomaltose and magnesium stearate). Clinical symptoms will be evaluated, and standardized questionnaires will be applied to assess the impact of fatigue, pain, anxiety-depression symptoms, sleep quality, dysautonomia, and quality of life. Heart rate variability (HRV) and orthostatic intolerance (10-min NASA Lean Test) will be performed to evaluate autonomic dysfunction. Sleep efficiency will be estimated through an actigraph sensor ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05454683
Study type	Interventional
Source	Laboratorios Viñas, S.A.
Contact	José Alegre, MD, PhD
Phone	+34934893000
Email	jalegre@vhebron.net
Status	Recruiting
Phase	N/A
Start date	September 5, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02075489` - Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans	N/A
Completed	`NCT01686074` - Motor Control in Chronic Fatigue Syndrome and Fibromyalgia	N/A
Completed	`NCT01651754` - Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome	N/A
Completed	`NCT00540254` - Behavioral Insomnia Therapy With Chronic Fatigue Syndrome	Phase 1/Phase 2
Active, not recruiting	`NCT00071162` - Genetics of Fibromyalgia	N/A
Withdrawn	`NCT04870476` - Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome	N/A
Completed	`NCT05730660` - Quercetin Phytosome® Chronic Fatigue Syndrome	N/A
Recruiting	`NCT04542161` - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Phase 2
Recruiting	`NCT03807973` - Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.	Phase 1
Recruiting	`NCT05719493` - Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)	N/A
Recruiting	`NCT05967052` - Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation	Phase 2
Terminated	`NCT01730495` - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome	Phase 2
Completed	`NCT01650636` - Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process	N/A
Completed	`NCT01156909` - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome	Phase 2
Completed	`NCT01046370` - A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia	N/A
Completed	`NCT00100412` - Hyporeactivity and Gulf War Illness	N/A
Recruiting	`NCT06128967` - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial	Phase 3
Completed	`NCT02669212` - Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health	N/A
Not yet recruiting	`NCT06011135` - Exploring Worry in CFS/ME
Active, not recruiting	`NCT03844412` - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome — MelatoZincME

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms